Yulia Slavina

Kura Oncology launches Caspian Therapeutics to advance menin inhibitors

Kura Oncology launches Caspian Therapeutics to advance menin inhibitors
Kura Oncology unveils Caspian Therapeutics

Kura Oncology has announced the launch of Caspian Therapeutics, a new separately financed company focused on the development of small-molecule menin inhibitors for diabetes and cardiometabolic diseases.

Drawing on Kura Oncology's expertise in scientific research and drug development related to menin inhibition, the Caspian Therapeutics team plans to drive forward new therapeutic options in the field. The move signals a strategic diversification for Kura Oncology into metabolic disease applications.

Kura Oncology has previously emphasized its commitment to patient-centered care and collaboration under the leadership of COO Kathy Ford, as detailed in a recent overview of company culture (/news/companies/show/3134835-kura-oncology-patient-culture/). The company has also engaged with the investment community by attending major conferences hosted by Wells Fargo and Cantor Fitzgerald (/news/companies/show/3211804-kura-oncology-investor-conferences/). These activities highlight Kura Oncology’s active role in both operational strategy and investor relations.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.